Ignite Creation Date:
2025-12-24 @ 11:43 PM
Ignite Modification Date:
2025-12-25 @ 9:35 PM
Study NCT ID:
NCT04428151
Status:
COMPLETED
Last Update Posted:
2025-12-04
First Post:
2020-06-09
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-06
Start Date Type:
ACTUAL
Primary Completion Date:
2024-05-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-10-30
Completion Date Type:
ACTUAL
First Submit Date:
2020-06-09
First Submit QC Date:
None
Study First Post Date:
2020-06-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-05-05
Results First Submit QC Date:
None
Results First Post Date:
2025-05-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-18
Last Update Post Date:
2025-12-04
Last Update Post Date Type:
ESTIMATED